Gerard A. Vreugdenhil

Eindhoven, NB, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 114 publications

Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti-PD-1-Based Treated Melanoma.

Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti-PD-1-Based Treated Melanoma.

Journal: JAMA oncology

Published: October 16, 2025

Carnitine Levels Decrease during Oxaliplatin Infusion: A Pilot Study.

Carnitine Levels Decrease during Oxaliplatin Infusion: A Pilot Study.

Journal: Chemotherapy

Published: April 16, 2025

Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry.

Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 28, 2025

Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.

Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.

Journal: British journal of cancer

Published: January 13, 2025

Corrigendum to "Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry" [Eur. J. Cancer 212, 2024, 115056].

Corrigendum to "Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry" [Eur. J. Cancer 212, 2024, 115056].

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 28, 2024

Changes in perception of prognosis in the last year of life of patients with advanced cancer and its associated factors: Longitudinal results of the eQuiPe study.

Changes in perception of prognosis in the last year of life of patients with advanced cancer and its associated factors: Longitudinal results of the eQuiPe study.

Journal: Palliative medicine

Published: December 04, 2024

Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy.

Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy.

Journal: British journal of cancer

Published: October 04, 2024

Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma.

Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma.

Journal: Immuno-oncology technology

Published: July 24, 2024

Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients.

Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients.

Journal: Cancers

Published: June 28, 2024

Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry.

Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 21, 2024

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

Journal: The New England journal of medicine

Published: June 03, 2024

Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study.

Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study.

Journal: Journal of the National Cancer Institute

Published: May 15, 2024

Showing 1-12 of 114

Last Updated: 09/26/2026